Plasma Fractionation Market 2014-2024 by Key Companies are CSL Behring, Green Cross Health, Octapharma, Novo Nordisk

Plasma fractionation is a method used for segregating plasma into its different components. Proteins present in plasma are mainly used for therapeutic purposes in the treatment of various diseases. Factors primarily responsible for the growth of the global plasma fractionation market are increased prevalence of rare diseases, surge in geriatric population, and growing use of immunoglobulins in different therapeutic domains.

Browse report sample at: https://www.psmarketresearch.com/market-analysis/plasma-fractionation-market/report-sample

On the basis of product type, the plasma fractionation market is categorized into immunoglobulins, coagulation factors, albumins, and protein inhibitors, wherein immunoglobulins hold the largest revenue share in the market. This is attributed to the rising prevalence of primary immunodeficiency disease (PIDD). For instance, treatment of PIDD is mainly dependent upon regular infusion therapy where immunoglobulins are involved in the treatment procedure. The market for albumins is expected to observe the fastest growth, owing to rapid use of the products in various drug formulations, especially for drugs used in treatment of acute liver diseases.

In the plasma fractionation market, laboratories, hospitals, and academic institutes are the prime end users. In 2018, hospitals are estimated to be the largest end-user category in the market, characterized by the availability of large and sophisticated devices; and presence of skilled professionals. Presence of different operating rooms and diagnosis facility in hospitals are predicted to boost the growth of the market for this category. This is due to the fact that a large number of equipment for testing and analysis are required in the hospitals.

Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=plasma-fractionation-market

The major growth driver for the plasma fractionation industry is the rising number of patients suffering from rare autoimmune diseases. According to the facts stated by National Institute of Environmental Health Sciences (NIEHS) in 2018, rare autoimmune diseases affect more than 23.5 million people in the U.S. Moreover, NIEHS also supports various clinical research institutes on how immunity and environmental factors work together to compromise the body’s ability to defend itself, and develop into autoimmune diseases. For instance, National Toxicology Program (NTP) by NIEHS is involved in researching on the link between genetic predisposition and environmental triggers.

Browse report at: https://www.psmarketresearch.com/market-analysis/plasma-fractionation-market

Key market players are focusing on the development of highly improved and technologically advanced products, to increase their share in the global plasma fractionation market. For instance, in December 2018, Novo Nordisk attained U.S. Food and Drug Administration (USFDA) approval for Novoeight, a drug manufactured by plasma fractionation method. This drug is used to treat patients suffering from hemophilia A.

Some of the other players operating in the plasma fractionation industry are CSL Behring, Japan Blood Products Organization, Green Cross Corp., Bio Product Laboratory Ltd., Octapharma AG, Kedrion S.p.A., and Grifols International S.A.

About P&S Intelligence

P&S Intelligence is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.